Related Experiment Video
Updated: Feb 24, 2026
The Successive Alleys Test of Anxiety in Mice and Rats
Published on: June 17, 2013
Preclinical rodent studies support minocycline as an adjunctive anxiolytic
D R Skvarc1, S C Lin2, S Croce3
1Deakin University, School of Medicine, IMPACT, Institute for Innovation in Physical and Mental Health and Clinical Translation, Geelong 3220, Australia; Deakin University, School of Psychology, Faculty of Health, Geelong 3220, Australia.
Abstract:
Anxiety disorders represent a significant public health burden with limited treatment options, particularly amidst the escalating rates observed over the past two decades. While psychological and pharmacological treatments are available, often these treatments do not facilitate complete symptom remission for many individuals. Consequently, there is a pressing need for innovative interventions. Current systematic reviews have provided clinical support for adjunctive minocycline in psychiatry, particularly schizophrenia and major depressive disorder. While anxiety symptoms have been investigated as secondary outcomes, there has been no direct clinical studies of minocycline and anxiety disorders. Additionally, there is no existing literature specifically exploring the biological mechanisms of minocycline relevant to the pathophysiology or presentation of anxiety disorders. This review investigated the potential of minocycline, a tetracycline antibiotic with anti-inflammatory, antioxidant, glutamatergic and neurogenic properties, as a potential treatment for anxiety disorders. Drawing upon existing preclinical literature, we explore the role of microglial activation in anxiety behavior, elucidating the relationship with neurotransmitter dysregulation, synaptic plasticity, and neuroendocrine functions. Preclinical evidence suggests that minocycline may modulate these pathways through its inhibitory effects on microglial activation, thereby mitigating neuroinflammation, restoring neurochemical balance, and alleviate anxious behaviors. Through a comprehensive analysis of available preclinical data, this review aims to inform future research on the potential utility of adjunctive minocycline in managing anxiety disorders.
Insights
Minocycline, an antibiotic, shows promise for treating anxiety disorders by reducing neuroinflammation and restoring neurochemical balance. Further research is needed to explore its potential as an adjunctive therapy for anxiety.
Area of Science:
- Neuroscience
- Psychiatry
- Pharmacology
Background:
- Anxiety disorders are a growing public health concern with limited treatment options.
- Current treatments often fail to achieve complete symptom remission.
- There is a need for novel therapeutic interventions for anxiety disorders.
Purpose of the Study:
- To investigate the potential of minocycline as a treatment for anxiety disorders.
- To explore the biological mechanisms underlying minocycline's effects on anxiety.
- To review preclinical evidence on minocycline's efficacy in anxiety-related pathways.
Main Methods:
- Systematic review of preclinical literature on minocycline and anxiety.
- Exploration of microglial activation's role in anxiety behavior.
- Analysis of minocycline's effects on neurotransmitter regulation, synaptic plasticity, and neuroendocrine function.
Main Results:
- Preclinical data suggest minocycline modulates anxiety-related pathways.
- Minocycline may reduce neuroinflammation by inhibiting microglial activation.
- Evidence indicates potential for restoring neurochemical balance and alleviating anxious behaviors.
Conclusions:
- Minocycline exhibits anti-inflammatory, antioxidant, glutamatergic, and neurogenic properties relevant to anxiety.
- Preclinical findings support minocycline's potential as an adjunctive treatment for anxiety disorders.
- Further clinical research is warranted to validate minocycline's utility in managing anxiety.
